{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:21:33Z","timestamp":1792178493218,"version":"4.4.0"},"reference-count":10,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.3201\/eid2801.204809","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T13:58:09Z","timestamp":1638453489000},"source":"Crossref","is-referenced-by-count":10,"title":["Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy"],"prefix":"10.3201","volume":"28","author":[{"given":"Nicolas","family":"Lambert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Dauby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Sadzot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Maquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2801.204809-202112192304-R1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"key-10.3201\/eid2801.204809-202112192304-R2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.coviro.2020.02.005","article-title":"Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy.","volume":"40","author":"Beck","year":"2020","journal-title":"Curr Opin Virol"},{"key":"key-10.3201\/eid2801.204809-202112192304-R3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"key-10.3201\/eid2801.204809-202112192304-R4","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","article-title":"Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?","volume":"79","author":"Antoniol","year":"2012","journal-title":"Neurology"},{"key":"key-10.3201\/eid2801.204809-202112192304-R5","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"key":"key-10.3201\/eid2801.204809-202112192304-R6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","article-title":"Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy.","volume":"60","author":"Tan","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.3201\/eid2801.204809-202112192304-R7","doi-asserted-by":"publisher","first-page":"ofz374","DOI":"10.1093\/ofid\/ofz374","article-title":"Sustained response and rationale of programmed cell death-1-targeting for progressive multifocal leukoencephalopathy.","volume":"6","author":"Audemard-Verger","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"key-10.3201\/eid2801.204809-202112192304-R8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/mi.2009.112","article-title":"PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.","volume":"3","author":"Akbari","year":"2010","journal-title":"Mucosal Immunol"},{"key":"key-10.3201\/eid2801.204809-202112192304-R9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","article-title":"Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.","volume":"45","author":"Kon","year":"2019","journal-title":"Drug Resist Updat"},{"key":"key-10.3201\/eid2801.204809-202112192304-R10","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3201\/eid2511.190705","article-title":"Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy.","volume":"25","author":"Medrano","year":"2019","journal-title":"Emerg Infect Dis"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/1\/20-4809_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:53:15Z","timestamp":1732989195000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/1\/20-4809_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2801.204809","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}